Session

PP 05 IBD (Posters)

NATURAL HISTORY OF ANAL STRICTURE IN PEDIATRIC-ONSET CROHN'S DISEASE: LONG-TERM FOLLOW-UP OF A POPULATION-BASED STUDY
NATURAL HISTORY OF ANAL STRICTURE IN PEDIATRIC-ONSET CROHN'S DISEASE: LONG-TERM FOLLOW-UP OF A POPULATION-BASED STUDY

REAL-WORLD UPTAKE OF STANDARD INDICES IN THE REPORTING OF ENDOSCOPY AND HISTOLOGY OF ULCERATIVE COLITIS: RESULTS OF A GLOBAL SURVEY
REAL-WORLD UPTAKE OF STANDARD INDICES IN THE REPORTING OF ENDOSCOPY AND HISTOLOGY OF ULCERATIVE COLITIS: RESULTS OF A GLOBAL SURVEY

USTEKINUMAB AND VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY FOR INFLAMMATORY BOWEL DISEASE IN CLINICAL PRACTICE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY
USTEKINUMAB AND VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY FOR INFLAMMATORY BOWEL DISEASE IN CLINICAL PRACTICE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY

ASSESSMENT OF PHYSICAL ACTIVITY LEVELS AND ITS BARRIERS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: THE “BE-FIT-IBD” STUDY RESULTS IN SOUTHERN EUROPE
ASSESSMENT OF PHYSICAL ACTIVITY LEVELS AND ITS BARRIERS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: THE “BE-FIT-IBD” STUDY RESULTS IN SOUTHERN EUROPE

ACHIEVEMENT OF STRINGENT EFFICACY ENDPOINTS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE TREATED WITH UPADACITINIB
ACHIEVEMENT OF STRINGENT EFFICACY ENDPOINTS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE TREATED WITH UPADACITINIB

ANTI-INFLAMMATORY EFFECTS OF HERICIUM ERINACEUS, BERBERINE, QUERCETIN, BIOTIN, AND NIACIN (HBQ-COMPLEX®) IN CROHN’S DISEASE AND ULCERATIVE COLITIS: AN EX VIVO TISSUE MODEL STUDY
ANTI-INFLAMMATORY EFFECTS OF HERICIUM ERINACEUS, BERBERINE, QUERCETIN, BIOTIN, AND NIACIN (HBQ-COMPLEX®) IN CROHN’S DISEASE AND ULCERATIVE COLITIS: AN EX VIVO TISSUE MODEL STUDY

EFFICACY OF INDUCTION UPADACITINIB THERAPY IN EAST ASIAN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
EFFICACY OF INDUCTION UPADACITINIB THERAPY IN EAST ASIAN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

PROACTIVE NATIONWIDE IBD PATIENT MONITORING AND MANAGEMENT USING PROMS - IMPLEMENTATION AND INITIAL RESULTS
PROACTIVE NATIONWIDE IBD PATIENT MONITORING AND MANAGEMENT USING PROMS - IMPLEMENTATION AND INITIAL RESULTS

NON-ALCOHOLIC FATTY LIVER DISEASE AND INFLAMMATORY BOWEL DISEASE – MORE QUESTIONS, TROUBLING ANSWERS
NON-ALCOHOLIC FATTY LIVER DISEASE AND INFLAMMATORY BOWEL DISEASE – MORE QUESTIONS, TROUBLING ANSWERS

MICROBIAL SIGNATURE OF PATIENTS WITH NEWLY DIAGNOSED CROHN’S DISEASE IDENTIFIES PATIENTS WITH COMPLICATED DISEASE COURSE
MICROBIAL SIGNATURE OF PATIENTS WITH NEWLY DIAGNOSED CROHN’S DISEASE IDENTIFIES PATIENTS WITH COMPLICATED DISEASE COURSE

ELDERLY INFLAMMATORY BOWEL DISEASE IN A TUNISIAN POPULATION
ELDERLY INFLAMMATORY BOWEL DISEASE IN A TUNISIAN POPULATION

THE NLRP3 INFLAMMASOME IS UPREGULATED ON MRNA EXPRESSION LEVEL AND ACTIVATED ON PROTEIN LEVEL IN INFLAMMATORY BOWEL DISEASE PATIENTS IN A SYSTEMATIC META-ANALYSIS AND IN A NEW OBSERVATIONAL STUDY COHORT
THE NLRP3 INFLAMMASOME IS UPREGULATED ON MRNA EXPRESSION LEVEL AND ACTIVATED ON PROTEIN LEVEL IN INFLAMMATORY BOWEL DISEASE PATIENTS IN A SYSTEMATIC META-ANALYSIS AND IN A NEW OBSERVATIONAL STUDY COHORT

MAINTENANCE OF CLINICAL BIOCHEMICAL AND TRANSMURAL REMISSION IN IBD PATIENTS SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB
MAINTENANCE OF CLINICAL BIOCHEMICAL AND TRANSMURAL REMISSION IN IBD PATIENTS SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB

ACCELERATED OR ESCALATED INDUCTION REGIMENS OF INFLIXIMAB FOR STEROID-REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS IN CLINICAL PRACTICE: DATA FORM THE ENEIDA REGISTRY
ACCELERATED OR ESCALATED INDUCTION REGIMENS OF INFLIXIMAB FOR STEROID-REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS IN CLINICAL PRACTICE: DATA FORM THE ENEIDA REGISTRY

ETS1 AND SENESCENCE ASSOCIATED SECRETORY PHENOTYPE INDUCTION IN HUMAN SMALL INTESTINAL FIBROBLASTS
ETS1 AND SENESCENCE ASSOCIATED SECRETORY PHENOTYPE INDUCTION IN HUMAN SMALL INTESTINAL FIBROBLASTS

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB FORMULATION DETERMINES A REDUCTION OF ANTIDRUG ANTIBODY LEVELS
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB FORMULATION DETERMINES A REDUCTION OF ANTIDRUG ANTIBODY LEVELS

RECOMBINANT CALPROTECTIN AS A PROMISING TOOL TO HARMONIZE MRP-8/MRP-14 IMMUNOASSAYS
RECOMBINANT CALPROTECTIN AS A PROMISING TOOL TO HARMONIZE MRP-8/MRP-14 IMMUNOASSAYS

HYDROGEN GAS INHALATION IMPROVED INTESTINAL MICROBIOTA IN ULCERATIVE COLITIS: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
HYDROGEN GAS INHALATION IMPROVED INTESTINAL MICROBIOTA IN ULCERATIVE COLITIS: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL

REAL-WORLD DATA IN INFLAMMATORY BOWEL DISEASES ON VEDOLIZUMAB THERAPY: INTERIM ANALYSIS OF THE NON-INTERVENTIONAL LISTEN II STUDY
REAL-WORLD DATA IN INFLAMMATORY BOWEL DISEASES ON VEDOLIZUMAB THERAPY: INTERIM ANALYSIS OF THE NON-INTERVENTIONAL LISTEN II STUDY

EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE TREATMENT IS INDEPENDENT FROM DISEASE ACTIVITY AND DOES NOT REQUIRE THERAPY OPTIMISATION IN CASE OF SILENT IBD WITH IDA – A PROSPECTIVE STUDY
EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE TREATMENT IS INDEPENDENT FROM DISEASE ACTIVITY AND DOES NOT REQUIRE THERAPY OPTIMISATION IN CASE OF SILENT IBD WITH IDA – A PROSPECTIVE STUDY

Item 621 - 640 / 826
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
32
33 34 35 36 37 38 39 40 41 42